ChromaDex Corporation (CDXC)

NASDAQ: CDXC · IEX Real-Time Price · USD
1.96
-0.01 (-0.51%)
At close: Jan 31, 2023, 4:00 PM
1.93
-0.03 (-1.53%)
Pre-market: Feb 1, 2023, 5:46 AM EST
-0.51%
Market Cap 145.96M
Revenue (ttm) 68.81M
Net Income (ttm) -20.45M
Shares Out 74.47M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 843,109
Open 1.92
Previous Close 1.97
Day's Range 1.81 - 2.02
52-Week Range 1.15 - 3.16
Beta 1.75
Analysts Buy
Price Target 6.18 (+215.31%)
Earnings Date Mar 8, 2023

About CDXC

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Robert Fried
Employees 115
Stock Exchange NASDAQ
Ticker Symbol CDXC
Full Company Profile

Financial Performance

In 2021, ChromaDex's revenue was $67.45 million, an increase of 13.82% compared to the previous year's $59.26 million. Losses were -$27.13 million, 36.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CDXC stock is "Buy." The 12-month stock price forecast is $6.18, which is an increase of 215.31% from the latest price.

Price Target
$6.18
(215.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported...

22 hours ago - Business Wire

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical st...

2 weeks ago - Business Wire

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Sci...

2 weeks ago - Business Wire

ChromaDex Named Brianna Gerber Chief Financial Officer

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Off...

3 weeks ago - Business Wire

ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising new findings based on a previously published clinical trial o...

1 month ago - Business Wire

Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for ChromaDex (CDXC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts ...

1 month ago - Zacks Investment Research

Here's Why ChromaDex (CDXC) is Poised for a Turnaround After Losing 7.5% in 4 Weeks

ChromaDex (CDXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...

1 month ago - Zacks Investment Research

ChromaDex Reports FDA's Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that on November 4, 2022, the U.S. FDA declared nicotinamide mono...

2 months ago - Business Wire

Bet on These 4 Top-Performing Liquid Stocks for Solid Returns

Here are four top-ranked liquid stocks, Oxford Industries (OXM), ChromaDex (CDXC), UserTesting (USER) and TravelCenters of America (TA), which investors can add to their portfolio for returns.

Other symbols: OXMTAUSER
3 months ago - Zacks Investment Research

ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 8.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

ChromaDex Corporation Reports Third Quarter 2022 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2022.

3 months ago - Business Wire

ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call o...

3 months ago - Business Wire

ChromaDex's Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo's (NHNE) Prestigious Nutrition Planet Awards

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that its consumer nicotinamide adenine dinucleotide (NAD+)...

3 months ago - Business Wire

ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #niagen--ChromaDex Corp. (NASDAQ:CDXC) (“the Company” or “ChromaDex”) a global bioscience company dedicated to healthy aging, announced today a new long term com...

4 months ago - Business Wire

ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CERP--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American C...

4 months ago - Business Wire

ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) (the “Company”), a global bioscience company dedicated to healthy aging, today announced that it has established a joint vent...

4 months ago - Business Wire

Sinopharm Xingsha to Introduce ChromaDex's Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen® at the major mainland China trade show, China International Nat...

4 months ago - Business Wire

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #HCPbrazil--ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen® and Tru Niagen® PRO in Braz...

5 months ago - Business Wire

Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer

Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture                                                      BOSTO...

Other symbols: DNA
5 months ago - PRNewsWire

Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex's Intellectual Property Held Under Exclusive License From Dartmouth College

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Office's Patent...

6 months ago - Business Wire

ChromaDex (CDXC) Reports Q2 Loss, Lags Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

ChromaDex Corporation Reports Second Quarter 2022 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022. Second Quarter 2022 and Recent Highlights Total net sa...

6 months ago - Business Wire

ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results f...

6 months ago - Business Wire

ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #DrCharlesBrenner--ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host a key opinion leader (KOL) webinar on the transforming benefits of nicotinamid...

7 months ago - Business Wire

ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ASN--ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CER...

8 months ago - Business Wire